[
    [
        {
            "time": "2021-03-31",
            "original_text": "健帆生物2020年度净利同比增53% 拟10派6.6元",
            "features": {
                "keywords": [
                    "健帆生物",
                    "2020年度",
                    "净利",
                    "同比增53%",
                    "10派6.6元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物2020年度净利同比增53% 拟10派6.6元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-31",
            "original_text": "健帆生物(300529.SZ)拟续聘致同会计师事务所为2021年度审计机构",
            "features": {
                "keywords": [
                    "健帆生物",
                    "续聘",
                    "致同会计师事务所",
                    "2021年度审计机构"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)拟续聘致同会计师事务所为2021年度审计机构",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-31",
            "original_text": "健帆生物(300529.SZ)2020年度归母净利同比升53.33%至8.75亿元 拟10派6.6元",
            "features": {
                "keywords": [
                    "健帆生物",
                    "2020年度",
                    "归母净利",
                    "同比升53.33%",
                    "8.75亿元",
                    "10派6.6元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)2020年度归母净利同比升53.33%至8.75亿元 拟10派6.6元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-31",
            "original_text": "健帆生物(300529.SZ)2020年度净利润升53.33%至8.75亿元 拟10派6.6元",
            "features": {
                "keywords": [
                    "健帆生物",
                    "2020年度",
                    "净利润",
                    "升53.33%",
                    "8.75亿元",
                    "10派6.6元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)2020年度净利润升53.33%至8.75亿元 拟10派6.6元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-31",
            "original_text": "健帆生物：2020年度净利润约8.75亿元，同比增长53.33%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "2020年度",
                    "净利润",
                    "8.75亿元",
                    "同比增长53.33%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：2020年度净利润约8.75亿元，同比增长53.33%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-31",
            "original_text": "健帆生物：2020年净利润同比增长53.33%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "2020年",
                    "净利润",
                    "同比增长53.33%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：2020年净利润同比增长53.33%",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]